INVO Fertility, Inc (NASDAQ:IVF) Shares Shorted: Short Interest Down 47.2% in October

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totaling 26,478 shares, a decrease of 47.2% from the September 30th total of 50,118 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average daily volume of 140,470 shares, the days-to-cover ratio is currently 0.2 days.

INVO Fertility Trading Down 10.9%

Shares of NASDAQ IVF traded down $0.23 on Friday, reaching $1.91. 129,525 shares of the company traded hands, compared to its average volume of 28,631. INVO Fertility has a fifty-two week low of $1.59 and a fifty-two week high of $106.32. The company has a 50 day moving average of $13.26 and a 200 day moving average of $37.03. The company has a current ratio of 0.71, a quick ratio of 0.67 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.20 million, a PE ratio of -0.06 and a beta of 2.39.

INVO Fertility (NASDAQ:IVF) last issued its earnings results on Friday, August 14th. The company reported $5.60 EPS for the quarter. The company had revenue of $2.18 million during the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INVO Fertility in a research note on Monday, August 3rd. Wall Street Zen upgraded shares of INVO Fertility to a “hold” rating in a report on Saturday, August 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $320.00.

INVO Fertility Company Profile

INVO Fertility, Inc is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment.

Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.

In addition to commercializing INVOcell, INVO Fertility operates and supports fertility centers that provide reproductive services, including IVF and related treatments.